NOT KNOWN FACTS ABOUT GLUCORAPHANIN

Hepatic impairment No dose adjustment is necessary in people with mild or average (Boy or girl-Pugh A or B) hepatic impairment (see portion 5.two). Exposure to midostaurin and its active metabolite CGP62221 is substantially reduce in sufferers with extreme hepatic impairment than that in individuals with normal hepatic functionality (see section fi